ChemSpider 2D Image | RG-2833 | C20H25N3O2

RG-2833

  • Molecular FormulaC20H25N3O2
  • Average mass339.431 Da
  • Monoisotopic mass339.194672 Da
  • ChemSpider ID30646723

More details:

Validated by Experts, Validated by Users, Non-Validated, Removed by Users

1215493-56-3 [RN]
17V14R89EU
Benzamide, N-[6-[(2-aminophenyl)amino]-6-oxohexyl]-4-methyl- [ACD/Index Name]
N-(2-aminophenyl)-6-[(4-methylphenyl)formamido]hexanamide
N-{6-[(2-Aminophenyl)amino]-6-oxohexyl}-4-methylbenzamid [German] [ACD/IUPAC Name]
N-{6-[(2-Aminophenyl)amino]-6-oxohexyl}-4-methylbenzamide [ACD/IUPAC Name]
N-{6-[(2-Aminophényl)amino]-6-oxohexyl}-4-méthylbenzamide [French] [ACD/IUPAC Name]
RG-2833
RGFP109
[1215493-56-3] [RN]
More...

Validated by Experts, Validated by Users, Non-Validated, Removed by Users

CCRIS 4693 [DBID]
  • Experimental Physico-chemical Properties
  • Miscellaneous

    • Bio Activity:

      Cell Cycle/DNA Damage MedChem Express HY-16425
      Cell Cycle/DNA Damage; MedChem Express HY-16425
      HDAC MedChem Express HY-16425
      RG2833 (RGFP109) is a brain-penetrant HDAC inhibitor with IC50 of 60 nM and 50 nM for HDAC1 and HDAC3, respectively. MedChem Express
      RG2833 (RGFP109) is a brain-penetrant HDAC inhibitor with IC50 of 60 nM and 50 nM for HDAC1 and HDAC3, respectively.; IC50 Value: 60 nM (HDAC1); 50 nM (HDAC3) [1]; Target: HDAC1/3; in vitro: RGFP109 dose-dependently upregulates frataxin mRNA and protein levels in cultures of unstimulated peripheral blood mononuclear cells (PBMC) obtained from FRDA patients [1].; in vivo: RG2833 (150 mg/kg) corrects frataxin deficiency and increases histone acetylation in the brain and heart of KIKI mice without acute toxicity signs [1]. MedChem Express HY-16425
      RG2833 (RGFP109) is a brain-penetrant HDAC inhibitor with IC50 of 60 nM and 50 nM for HDAC1 and HDAC3, respectively.;IC50 Value: 60 nM (HDAC1); 50 nM (HDAC3) [1];Target: HDAC1/3;In vitro: RGFP109 dose-dependently upregulates frataxin mRNA and protein levels in cultures of unstimulated peripheral blood mononuclear cells (PBMC) obtained from FRDA patients [1].;In vivo: RG2833 (150 mg/kg) corrects frataxin deficiency and increases histone acetylation in the brain and heart of KIKI mice without acute toxicity signs [1]. RGFP109 ameliorates the disease phenotype of a Friedreich ataxia mouse model [2]. RGFP109 (30 mg/kg p.o.) also alleviates established l-DOPA-induced dyskinesia [3].Clinical trial: Phase 1 MedChem Express HY-16425

Predicted data is generated using the ACD/Labs Percepta Platform - PhysChem Module, version: 14.00

Density: 1.2±0.1 g/cm3
Boiling Point: 620.1±50.0 °C at 760 mmHg
Vapour Pressure: 0.0±1.8 mmHg at 25°C
Enthalpy of Vaporization: 91.9±3.0 kJ/mol
Flash Point: 328.8±30.1 °C
Index of Refraction: 1.611
Molar Refractivity: 101.3±0.3 cm3
#H bond acceptors: 5
#H bond donors: 4
#Freely Rotating Bonds: 8
#Rule of 5 Violations: 0
ACD/LogP: 2.29
ACD/LogD (pH 5.5): 2.51
ACD/BCF (pH 5.5): 46.57
ACD/KOC (pH 5.5): 529.35
ACD/LogD (pH 7.4): 2.55
ACD/BCF (pH 7.4): 51.22
ACD/KOC (pH 7.4): 582.24
Polar Surface Area: 84 Å2
Polarizability: 40.2±0.5 10-24cm3
Surface Tension: 51.6±3.0 dyne/cm
Molar Volume: 291.8±3.0 cm3

Click to predict properties on the Chemicalize site


Advertisement